Interactions between antiparkinsonian drugs and ABCB1/P-glycoprotein at the blood-brain barrier in a rat brain endothelial cell model

Neuroscience Letters

Volumn 442, Issue 1, 2008, Pages 19-23

  Vautier, Sarah ^a   Milane, Aline ^a   Fernandez, Christine ^a,b   Buyse, Marion ^a   Chacun, Helene ^a   Farinotti, Robert ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

ABCB1; Blood brain barrier; Bromocriptine; Drug drug interaction

Indexed keywords

BROMOCRIPTINE; DIGOXIN; GLYCOPROTEIN P; LEVODOPA; MULTIDRUG RESISTANCE PROTEIN 1; PERGOLIDE; PRAMIPEXOLE; RHODAMINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; ENDOTHELIUM CELL; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPARKINSON AGENTS; BLOOD-BRAIN BARRIER; BRAIN; CELL LINE; ENDOTHELIAL CELLS; P-GLYCOPROTEIN; RATS;

EID: 47749102057     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.06.055     Document Type: Article

References (22)

1. Adler C.H., and Thorpy M.J. Sleep issues in Parkinson's disease. Neurology 64 (2005) S12-20
2. Avorn J., Schneeweiss S., Sudarsky L.R., Benner J., Kiyota Y., Levin R., and Glynn R.J. Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch. Neurol. 62 (2005) 1242-1248
3. Fischer V., Rodriguez-Gascon A., Heitz F., Tynes R., Hauck C., Cohen D., and Vickers A.E. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab. Dispos. 26 (1998) 802-811
4. Greenwood J., Pryce G., Devine L., Male D.K., dos Santos W.L., Calder V.L., and Adamson P. SV40 large T immortalised cell lines of the rat blood-brain and blood-retinal barriers retain their phenotypic and immunological characteristics. J. Neuroimmunol. 71 (1996) 51-63
5. Homann C.N., Wenzel K., Suppan K., Ivanic G., Kriechbaum N., Crevenna R., and Ott E. Sleep attacks in patients taking dopamine agonists: review. BMJ 324 (2002) 1483-1487
6. Keogh J.P., and Kunta J.R. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur. J. Pharm. Sci. 27 (2006) 543-554
7. Langdon N., Malcolm P.N., and Parkes J.D. Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease. Clin. Neuropharmacol. 9 (1986) 440-447
8. Loscher W., and Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol. 76 (2005) 22-76
9. Maurer G., Schreier E., Delaborde S., Loosli H.R., Nufer R., and Shukla A.P. Fate and disposition of bromocriptine in animals and man. I. Structure elucidation of the metabolites. Eur. J. Drug Metab. Pharmacokinet. 7 (1982) 281-292
10. Maurer G., Schreier E., Delaborde S., Nufer R., and Shukla A.P. Fate and disposition of bromocriptine in animals and man. II. Absorption, elimination and metabolism. Eur. J. Drug Metab. Pharmacokinet. 8 (1983) 51-62
11. Nelson M.V., Berchou R.C., Kareti D., and LeWitt P.A. Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine. Clin. Pharmacol. Ther. 47 (1990) 694-697
12. Orlowski S., Valente D., Garrigos M., and Ezan E. Bromocriptine modulates P-glycoprotein function. Biochem. Biophys. Res. Commun. 244 (1998) 481-488
13. Paus S., Brecht H.M., Koster J., Seeger G., Klockgether T., and Wullner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov. Disord. 18 (2003) 659-667
14. Regina A., Romero I.A., Greenwood J., Adamson P., Bourre J.M., Couraud P.O., and Roux F. Dexamethasone regulation of P-glycoprotein activity in an immortalized rat brain endothelial cell line, GPNT. J. Neurochem. 73 (1999) 1954-1963
15. Schran H.F., Bhuta S.I., Schwarz H.J., and Thorner M.O. The pharmacokinetics of bromocriptine in man. Adv. Biochem. Psychopharmacol. 23 (1980) 125-139
16. Shiraki N., Okamura K., Tokunaga J., Ohmura T., Yasuda K., Kawaguchi T., Hamada A., and Nakano M. Bromocriptine reverses P-glycoprotein-mediated multidrug resistance in tumor cells. Jpn. J. Cancer Res. 93 (2002) 209-215
17. Soares-Da-Silva P., and Serrao M.P. Outward transfer of dopamine precursor l-3,4-dihydroxyphenylalanine (l-dopa) by native and human P-glycoprotein in LLC-PK(1) and LLC-GA5 col300 renal cells. J. Pharmacol. Exp. Ther. 293 (2000) 697-704
18. Sun H., Dai H., Shaik N., and Elmquist W.F. Drug efflux transporters in the CNS. Adv. Drug Deliv. Rev. 55 (2003) 83-105
19. Tsuji A., Tamai I., Sakata A., Tenda Y., and Terasaki T. Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein. Biochem. Pharmacol. 46 (1993) 1096-1099
20. Uhr M., Ebinger M., Rosenhagen M.C., and Grauer M.T. The anti-Parkinson drug budipine is exported actively out of the brain by P-glycoprotein in mice. Neurosci. Lett. 383 (2005) 73-76
21. Vautier S., Fernandez C., Milane A., Lacomblez L., Davrinche C., and Farinotti R. ABCB1 (P-glycoprotein) and blood-brain barrier: role in neurological diseases and their treatments. J. Pharm. Clin. 25 (2006) 225-235
22. Vautier S., Lacomblez L., Chacun H., Picard V., Gimenez F., Farinotti R., and Fernandez C. Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood-brain barrier in the mouse. Eur. J. Pharm. Sci. 27 (2006) 167-174